Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates

John W. Sanders,Daniel Ewing,Appavu K. Sundaram,Christopher Scott Gamble,Maria Blevins,Zhaodong Liang,Leigh Ann Sanders,David A. Ornelles,Peifang Sun,Klara Lenart,Hendrik Feuerstein,Karin Loré,Nikolai Petrovsky,Maya Williams,Kevin R. Porter

DOI: https://doi.org/10.3390/vaccines12050451

2024-04-24

Vaccines

Abstract:COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has significantly impacted public health and the economy worldwide. Most of the currently licensed COVID-19 vaccines act by inhibiting the receptor-binding function of the SARS-CoV-2 spike protein. The constant emergence of SARS-CoV-2 variants resulting from mutations in the receptor-binding domain (RBD) leads to vaccine immune evasion and underscores the importance of broadly acting COVID-19 vaccines. Inactivated whole virus vaccines can elicit broader immune responses to multiple epitopes of several antigens and help overcome such immune evasions. We prepared a psoralen-inactivated SARS-CoV-2 vaccine (SARS-CoV-2 PsIV) and evaluated its immunogenicity and efficacy in nonhuman primates (NHPs) when administered with the Advax-CpG adjuvant. We also evaluated the SARS-CoV-2 PsIV as a booster shot in animals vaccinated with a DNA vaccine that can express the full-length spike protein. The Advax-CpG-adjuvanted SARS-CoV-2 PsIV elicited a dose-dependent neutralizing antibody response in the NHPs, as measured using a serum microneutralization assay against the SARS-CoV-2 Washington strain and the Delta variant. The animals vaccinated with the DNA vaccine followed by a boosting dose of the SARS-CoV-2 PsIV exhibited the highest neutralizing antibody responses and were able to quickly clear infection after an intranasal challenge with the SARS-CoV-2 Delta variant. Overall, the data show that the Advax-CpG-adjuvanted SARS-CoV-2 PsIV, either by itself or as a booster shot following nucleic acid (NA) vaccines, has the potential to protect against emerging variants.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the immunogenicity and protective efficacy of a new type of psoralen - inactivated SARS - CoV - 2 vaccine (SARS - CoV - 2 PsIV) in non - human primates. Specifically, the researchers hope to understand whether this vaccine can:

1. **Induce neutralizing antibody responses**: Evaluate the immunogenicity of the vaccine by detecting the neutralizing antibody levels against the SARS - CoV - 2 Washington strain and the Delta variant using the serum microneutralization assay.
2. **Effect as a booster shot**: Evaluate the effect of SARS - CoV - 2 PsIV as a DNA vaccine booster shot, especially in animals that have been vaccinated with a DNA vaccine expressing the full - length spike protein.
3. **Ability to combat viral challenges**: Evaluate its protective efficacy by observing the speed of infection clearance in vaccinated animals after intranasal challenge with the SARS - CoV - 2 Delta variant.

The research background indicates that most current COVID - 19 vaccines mainly target the receptor - binding domain (RBD) of the SARS - CoV - 2 spike protein. However, with the continuous emergence of virus variants, the risk of immune evasion of these vaccines increases. Therefore, it is particularly important to develop whole - virus inactivated vaccines that can induce a broad immune response. Psoralen - inactivated vaccines are expected to overcome this problem and provide broader protection by retaining the natural conformation of the viral surface antigens.